SL-846 / Shattuck - LARVOL DELTA

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026 (GlobeNewswire)

Preclinical • Inflammatory Bowel Disease

DEVELOPMENT AND CHARACTERIZATION OF SL-846: A HALF-LIFE EXTENDED, DUAL-RECEPTOR (DR3 X IL23RA) TARGETING BISPECIFIC ANTIBODY (UEGW 2026) - "However, TL1A blocking monoclonal antibodies cause high rates of anti-drug antibody formation, and this propensity was compounded in a bispecific format, leading to >95% ADA, nearly all neutralizing, in the case of AMG966 (TL1A x TNFα) and RG6730 (TL1A x IL-23p40)...In healthy donor and IBD patient PBMC assays, SL-846 blocked combined TL1A- and IL-23–induced IFNγ, IL-17A/F and IL-22 production with efficacy equivalent to individual monotherapy agents or combined SL-325 (anti-DR3 mAb) plus Risankizumab or icotrokinra treatment controls... Together, these data demonstrate that SL-846 is a potent, dual-specific antagonist of TL1A and IL-23 signaling. Its dual-receptor targeting and durable antagonism support its potential as a first-in-class bispecific therapeutic with superior efficacy prospects for the treatment of IL-23 and TL1A-driven inflammatory diseases."

Bispecific • Gastroenterology • Gastrointestinal Disorder • Inflammatory Bowel Disease • CD123 • IFNG • IL17A • IL22 • IL23A • TNFA

Shattuck’s lead bispecific product candidate, SL-846, is a potentially first-in-class, half-life extended DR3 x IL-23 receptor blocking antibody for the treatment of inflammatory and immune-mediated diseases. (GlobeNewswire) - "SL-846 is currently being evaluated in an ongoing IND-enabling GLP toxicology study in non-human primates; Preclinical data for SL-846, including safety, pharmacokinetics, and receptor occupancy from the ongoing GLP toxicology study are expected to be presented in a poster at UEG Week, to be held October 17-20, 2026; Shattuck expects to initiate a Phase 1 healthy volunteer clinical trial of SL-846 and report initial data in 2027."

New P1 trial • Preclinical • Immunology • Inflammation

SL-846: A Dual DR3 and IL-23 Receptor Blocking Antibody (GlobeNewswire) - "SL-846 is an Fc-silenced, half-life extended, IgG1 bispecific antibody; Preclinical data demonstrated that SL-846 was equipotent, or more potent, than sequence equivalents of risankizumab and icotrokinra controls in multiple in vitro and cell-based potency assays; SL-846 is currently being evaluated in an ongoing IND-enabling GLP toxicology study in non-human primates. Safety and immunogenicity data are expected in the second half of 2026; Shattuck expects to submit an IND for SL-846 in the first half of 2027."

IND • Preclinical • Inflammatory Bowel Disease